SYNAIRGEN PLC LS-,01

Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive about the company's recent fundraising efforts to support a phase II clinical trial. The study aims to test SNG001, a broad-spectrum inhaled antiviral, in critically ill patients requiring mechanical ventilation due to respiratory viruses.» Mehr auf proactiveinvestors.co.uk

Synairgen PLC (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £25 million to fund the development of SNG001, its investigational inhaled interferon beta treatment. The funding includes a subscription for between £18-£19 million and a £6 million placing and open offer.» Mehr auf proactiveinvestors.co.uk

Synairgen PLC (AIM:SNG, OTC:SYGGF) said it has made 'substantial progress' preparing for a phase II trial of its lead asset, SNG001, which is being developed to treat high-risk patients with severe viral lung infections who are on ventilation. "Having closely analysed various routes forward, we are confident that our focus on these high-risk patients is optimal from both a clinical and commercial perspective," said CEO Richard Marsden.» Mehr auf proactiveinvestors.co.uk